Skip to main content
OABI
NASDAQ Industrial Applications And Services

OmniAb Reports Significant 2025 Revenue Decline and Increased Loss, Projects 2026 Revenue Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.75
Mkt Cap
$260.559M
52W Low
$1.22
52W High
$3.46
52W Position info
43% above low
Off High info
49% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

OABI sits 43% above its 52-week low of $1.22.

Summary

OmniAb, Inc. announced a significant 29% revenue decline and increased net loss for the full year 2025, but provided 2026 guidance projecting revenue growth and continued cash burn.


Key Events · Earnings and Guidance · OABI

  • Full Year 2025 Financial Results

    Revenue for 2025 decreased 29% year-over-year to $18.7 million, and the net loss increased to $64.8 million, or $0.57 per share.

  • Fourth Quarter 2025 Performance

    Q4 2025 revenue declined 22% to $8.4 million compared to Q4 2024, with a net loss of $14.2 million, or $0.11 per share.

  • 2026 Financial Guidance

    OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and projects to end the year with cash and cash equivalents between $30 million and $35 million.

  • Strategic Business Updates

    The company launched OmniUltra™, a new transgenic chicken technology, and reported 107 active partners and 407 active programs as of December 31, 2025.


Analysis · OABI · Industrial Applications And Services

OmniAb, Inc. reported a substantial 29% year-over-year revenue decrease for the full year 2025, reaching $18.7 million, alongside an increased net loss of $64.8 million. Fourth-quarter results mirrored this trend with a 22% revenue decline and a higher net loss. This poor performance is a significant negative signal regarding the company's recent operational execution. However, the company provided 2026 revenue guidance of $25 million to $30 million, indicating an expected recovery and growth from the 2025 figures. The projected year-end cash balance of $30 million to $35 million suggests continued cash burn, but the company maintains a runway. Investors should monitor the execution of the 2026 guidance and the impact of new initiatives like OmniUltra™ and partner program advancements on future revenue and profitability.

At the time of this filing, OABI was trading at $1.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $260.6M. The 52-week trading range was $1.22 to $3.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OABI - Latest Insights

OABI
May 07, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $2.00 info
Change: +$0.530 (+36%) info
Market Cap: $285.596M info
OABI
May 07, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $2.00 info
Change: +$0.530 (+36%) info
Market Cap: $285.596M info
OABI
Mar 04, 2026, 4:40 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.75
Real-time Price: $2.00 info
Change: +$0.250 (+14%) info
Market Cap: $285.596M info
OABI
Mar 04, 2026, 4:28 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $1.75
Real-time Price: $2.00 info
Change: +$0.250 (+14%) info
Market Cap: $285.596M info